241 related articles for article (PubMed ID: 27564113)
21. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
22. Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in
Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB
Mol Cancer Res; 2020 Dec; 18(12):1767-1776. PubMed ID: 32801162
[TBL] [Abstract][Full Text] [Related]
23. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
[TBL] [Abstract][Full Text] [Related]
24. [Estradiol activates MAPK signaling pathway by estrogen induced VEGF and bFGF in endometrial cancer cells].
Lu Y; Jiang S; Zhang J; Song H; Li L
Zhonghua Fu Chan Ke Za Zhi; 2014 Dec; 49(12):925-31. PubMed ID: 25608994
[TBL] [Abstract][Full Text] [Related]
25. Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets.
Kanojia D; Garg M; Martinez J; M T A; Luty SB; Doan NB; Said JW; Forscher C; Tyner JW; Koeffler HP
J Hematol Oncol; 2017 Nov; 10(1):173. PubMed ID: 29132397
[TBL] [Abstract][Full Text] [Related]
26. Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR‑FGFR1 fusion.
Qiu XH; Li F; Cao HQ; Shao JJ; Mei JG; Li HQ; Zhai YP
Mol Med Rep; 2017 Mar; 15(3):1024-1030. PubMed ID: 28138694
[TBL] [Abstract][Full Text] [Related]
27. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
[TBL] [Abstract][Full Text] [Related]
28. Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways.
Subramonian D; Phanhthilath N; Rinehardt H; Flynn S; Huo Y; Zhang J; Messer K; Mo Q; Huang S; Lesperance J; Zage PE
Br J Cancer; 2020 Aug; 123(4):568-579. PubMed ID: 32457362
[TBL] [Abstract][Full Text] [Related]
29. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
Iyer R; Wehrmann L; Golden RL; Naraparaju K; Croucher JL; MacFarland SP; Guan P; Kolla V; Wei G; Cam N; Li G; Hornby Z; Brodeur GM
Cancer Lett; 2016 Mar; 372(2):179-86. PubMed ID: 26797418
[TBL] [Abstract][Full Text] [Related]
30. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
Fan YH; Cheng J; Vasudevan SA; Dou J; Zhang H; Patel RH; Ma IT; Rojas Y; Zhao Y; Yu Y; Zhang H; Shohet JM; Nuchtern JG; Kim ES; Yang J
Cell Death Dis; 2013 Oct; 4(10):e867. PubMed ID: 24136231
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumor effect of AZD8055 against neuroblastoma cells in vitro and in vivo.
Xu DQ; Toyoda H; Yuan XJ; Qi L; Chelakkot VS; Morimoto M; Hanaki R; Kihira K; Hori H; Komada Y; Hirayama M
Exp Cell Res; 2018 Apr; 365(2):177-184. PubMed ID: 29499203
[TBL] [Abstract][Full Text] [Related]
32. Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib.
Englinger B; Laemmerer A; Moser P; Kallus S; Röhrl C; Pirker C; Baier D; Mohr T; Niederstaetter L; Meier-Menches SM; Gerner C; Gabler L; Gojo J; Timelthaler G; Senkiv J; Jäger W; Kowol CR; Heffeter P; Berger W
Int J Cancer; 2020 Sep; 147(6):1680-1693. PubMed ID: 32064608
[TBL] [Abstract][Full Text] [Related]
33. Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma.
Mao X; Chen Z; Zhao Y; Yu Y; Guan S; Woodfield SE; Vasudevan SA; Tao L; Pang JC; Lu J; Zhang H; Zhang F; Yang J
Oncotarget; 2017 Jan; 8(1):1555-1568. PubMed ID: 27902463
[TBL] [Abstract][Full Text] [Related]
34. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways.
Cheng J; Fan YH; Xu X; Zhang H; Dou J; Tang Y; Zhong X; Rojas Y; Yu Y; Zhao Y; Vasudevan SA; Zhang H; Nuchtern JG; Kim ES; Chen X; Lu F; Yang J
Cell Death Dis; 2014 Feb; 5(2):e1079. PubMed ID: 24556694
[TBL] [Abstract][Full Text] [Related]
35. Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.
Ren M; Qin H; Ren R; Cowell JK
Leukemia; 2013 Jan; 27(1):32-40. PubMed ID: 22781593
[TBL] [Abstract][Full Text] [Related]
36. Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.
Kim DH; Kwak Y; Kim ND; Sim T
Cancer Biol Ther; 2016; 17(1):65-78. PubMed ID: 26574622
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
38. The ponatinib/gossypol novel combination provides enhanced anticancer activity against murine solid Ehrlich carcinoma via triggering apoptosis and inhibiting proliferation/angiogenesis.
El-Lakkany NM; Elkattan HH; Elsisi AE
Toxicol Appl Pharmacol; 2021 Dec; 432():115767. PubMed ID: 34699866
[TBL] [Abstract][Full Text] [Related]
39. RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance.
Salm F; Cwiek P; Ghosal A; Lucia Buccarello A; Largey F; Wotzkow C; Höland K; Styp-Rekowska B; Djonov V; Zlobec I; Bodmer N; Gross N; Westermann F; Schäfer SC; Arcaro A
Oncogene; 2013 Aug; 32(34):3944-53. PubMed ID: 23027129
[TBL] [Abstract][Full Text] [Related]
40. Ponatinib Combined With Rapamycin Causes Regression of Murine Venous Malformation.
Li X; Cai Y; Goines J; Pastura P; Brichta L; Lane A; Le Cras TD; Boscolo E
Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):496-512. PubMed ID: 30626204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
